Bi- and Tri-Specific Antibody Therapies

• 5529 · PDF Preclinical characterization of LY4336619, a novel ALPPL2xCD3 bispecific antibody, for the treatment of ovarian and endometrial cancer Colleen Burns, Julie Dobkin, Kevin Lindquist, Hee Rae Shin, Cindy Nguyen, Wei Yang, Xiaodong Huang, Marie Mutryn, Whitney S. Helms, Nicholas Arce, Yvonne Mak, Alexandra Antonoplis, Amelie Forest, Abraham Abouzeid, Marta Witek, Claire F. Friedman, Zhao Hai Lu, Mohan Srinivasan, Kyla Driscoll, Andrew Hass, Omar Duramad, Rikke Holmgaard, Kristin Bedard
• 5530 · PDF Preclinical validation of the antitumor activity and safety of M0324, a novel MUC-1 conditional CD40 agonist, and its combination with immune checkpoint inhibitors (ICIs), for selective immune activation Weixiao Sha, Jing Ni, Anika Bergmann, Nathalie Duncan, Bo Marelli, Feng Jiang, Julia Marie Mueller, Sina Junkers, Christina Hubl, Ivana Durutovic, Sonia Jaramillo, Paul D. Lyne, Laura Helming
• 5532 · PDF Bispecific antibodies targeting EGFR and HER2 for effective killing of solid tumor cells via a safe CD47-SIRPA modulation Eric Hatterer, Vanessa Buatois, Alizée Viandier, Emeline Rousset, Cécile Raymond, Adeline Lesnier, Pauline Lloveras, Christelle Mougin, Ulla Ravn, Pauline Malinge, Frederic Bollin, Limin Shang, Walter Ferlin, Nicolas Fischer, Jose Saro, Krzysztof Masternak
• 5533 · PDF VISTA×MSLN bispecific antibody-directed therapies as a biomarker-guided strategy for epithelioid malignant pleural mesothelioma Sang Moo Lee, Hee geon Park, Gyo-Jin Choi, Myeung Ryun Seo, Ji Eun Park, Seok Gyeong Yun, Na Eun Jeong, Soo Jin Ryu, Yeong Jeong Jeon, Yoon La Choi, Sung Youl Hong, Young Kee Shin
• 5534 · PDF INCA036873, a first-in-class CD70×CD3 T cell-redirecting bispecific antibody, for the treatment of CD70-positive malignancies Yao-Bin Liu, Charlie Kang, Christina Stevens, Lifeng Zhang, Daniel Merenich, Emily Ren, Chifei Sun, Lu Huo, Taylor Getty, Heather Bullins, Zhiwan Dong, Zhiying Ji, Michelle Kinder, Jun Guan, Tessa Steevels, Femke Feenstra, Rinse Klooster, David Maussang-Detaille, Cynthia Timmers, Jonathan Rios-Doria, Horacio Nastri, Jeff Jackson, Patrick Mayes, Chryssa Kanellopoulou
• 5535 · PDF GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma Hayley Roth, Trevor Barnes, Daniel Rogers, Ileine Sanchez, Lewis Joe Stafford, Valerie Firers, Breanna Tyrell, Amelia M. Snyder, Kyle Doolan, Benjamin J. Doranz, Ross Chambers, Joseph B. Rucker
• 5536 · PDF Preclinical immunotoxicity assessment of bispecific antibodies using an ex vivo circulating human whole blood assay Helena Harlin Laven, Louise Nilsson, Marika Pettersson, Gunilla Törnqvist, Erika Fletcher, Sakthi Ponandai-Srinivasan, Sara Mangsbo, Alexander Kele
• 5537 · PDF A half-life extended PD-1×VEGFA bispecific antibody demonstrates potent anti-tumor activity in preclinical models Frank An, Weiqiu Lan, Baihong Liu, Yang Chen, Xi Yang, Jinhua Zhao, Gao An, Yi Yang
• 5538 · PDF Pan-alphabeta-T-cell reactive anti-TCR VHH bispecifics demonstrate potent cytotoxicity through novel constant region targeting Michael B. Battles
• 5539 · PDF The anti-tumor activity of BB-202, a novel anti-PD-1/anti-VEGF bispecific antibody Hongyan Zhong, Daniel Guo, Phuong Nguyen, Daniel Li, Ming Yang
• 5540 · PDF SCR-M015, a PD-1/VEGF bispecific antibody exhibits potent anti-tumor efficacy in preclinical studies Qiong Wang, Yayuan Fu, Fengli Shan, Yanqiu Wang, Guimei Yang, Yan Wang, Xiaokang Qin, Renhong Tang
• 5541 · PDF Characterization and functional evaluation of PF-08634404 (SSGJ-707) a tetravalent PD-1 x VEGF bispecific for the treatment of cancer Ryan A. Heiser, Meghan Zuck, Catalina Sakai, Eliana Moskovitz, Laila Shehata, Markus Carlson, Florian Heinkel, Sherif Abdelhamed, MIchelle Ulrich, Matt Rathgeber, Brian P. O'Connor, Joseph D. Dekker, Haomin Huang, Sharsti Sandall
• 5542 · PDF Novel PD-1xVEGFxIL-2 trispecific immune modulator with superior safety and greater efficacy Lei Wu, Mengmeng Sun, Bowei Liao, Shuang Wang, Tengfei Yu, Jijie Gu
• 5543 · PDF Mechanism-driven cell-based assays to screen & characterize bi-specific antibodies Venkatesh Chari, Surekha Bonasu, Luhan Yang, Jennifer Lin-Jones, Jane Lamerdin, Alpana Prasad, Gaurav Agrawal
• 5544 Organoid-T cell co-cultures: A robust platform for bispecific antibody immunotherapy development Sonia Aristin Revilla, Cesar Oyarce, Sumeyra Mucuk, Javier Frias Aldeguer, Timo Voskuilen, Merel Derksen, Farzin Pourfarzad, Robert G. J. Vries, Sylvia F. Boj
• 5545 · PDF Collagen-binding anti-GITR antibody reshapes immunosuppressive microenvironment and prolongs survival in recurrent glioblastoma Jun Takei, Chuyi Wang, Ken Furudate, Opeyemi Iwaloye, Lewis Barr, Haruka Ichie, Shunsuke Tsuzuki, Jun Ishihara, Satoru Osuka
• 5546 · PDF Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC Jun Ren, Ngan Mitchell, Marie Boutet, Vladimir Roudko, Jeremy Ratiu, Jorge Blando, Sophia Varriano, Elizabeth Galery, Rebecca Halpin, Trevor Connor, Kanam Malhotra, Bartholomew Starich, Jessica Wagner, Yi Luan, Anna Huntley, Joseph Boland, Maurizio Scaltriti, Mark Cobbold, Simon Hollingsworth, Scott Hammond, Doug Palmer, Paul Chariou, Kristen Pollizzi, Daniela Dinulescu
• 5547 · PDF Enhancing antibody-dependent cellular cytotoxicityin mesothelioma through concurrent EGFR and MET targeting withamivantamab Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Jennifer Ayers-Ringler, Lin Yang, Katherine E. R. Smith, Farhad Kosari, Aaron S. Mansfield
• 5548 · PDF Unbiased discovery of novel macrophage-activating immunotherapies for ALK+ non-small cell lung cancer Carlota Pages-Geli, Thomas Wienclaw, Juliano Ribeiro, Matheus Silva, Kipp Weiskopf
• 5549 · PDF Non-clinical modeling the therapeutic window of HX044, a novel CTLA4xCD47 BsAb Hang Ke, Zihan Xu, Tao Yang, Cen Chen, Sheng Gao, Lei Zhang, Faming Zhang, Henry Li
• 5550 · PDF T cell transcriptome is altered by Talquetamab in presence of GPRC5D on MM cells Umair Munawar, Alexander Leipold, Seungbin Han, Silvia Nerreter, Shilpa Kurian, Emma Besant, Nina Rein, Johanna Lehmann, Max Koeppel, Xiang Zhou, Ondrej Slaby, Hermann Einsele, Leo Rasche, Emmanual Saliba, Johannes Waldschmidt, Martin Kortuem
• 5551 · PDF MHC class II targeted immunotherapy in the treatment of pancreatic cancer Reeder Robinson, Leticia Reyes, Samaneh Saberi, Lena Golick, Sandeep Gupta, Michael Ostrowski, Nathan G. Dolloff
• 5552 · PDF MHC class II engager immunotherapy for the treatment of acute myeloid leukemia Lena Golick, Reeder Robinson, Leticia Reyes, Sandeep Gupta, Nathan G. Dolloff
• 5553 · PDF Tumor-selective activation of 4-1BB receptor via bispecific antibody combinations Lucie Diby, Pauline Malinge, Valery Moine, Lise Nouveau, Laurence Chatel, Krzysztof Masternak, Limin Shang, Walter Ferlin, Nicolas Fischer, Jose Saro, Mikael Pittet, Vanessa Buatois, Eric Hatterer
• 5554 · PDF Anti-human CTLA-4×TIGIT bispecific antibody: A novel immunotherapy specifically targeting tumor-infiltrating FOXP3+ regulatory T cells Soojin Ryu, Hee Geon Park, Sang Beom Bang, Ji Hye Nam, Ho Jin Lee, Ju Yeon Seo, Gun Yi Ahn, Myeung Ryun Seo, Sang Moo Lee, Yoon La Choi, Sung Youl Hong, Young Kee Shin

在完整检索应用中浏览本分会场 →